Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride

Journal of Clinical Pharmacology

Volumn 39, Issue 12, 1999, Pages 1263-1271

  Corey, A ^a   Agnew, J ^a   Brum, J ^a   Parekh, N ^a   Valentine, S ^a   Williams, M ^a  

^a Otsuka America Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIMILIDE; DRUG METABOLITE; NE 10171; NE 11178; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CIRCADIAN RHYTHM; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; QT INTERVAL;

EID: 0033323790     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922012079     Document Type: Article

References (21)

1. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents
2. Effect of channel modulation and pH on I(sκ) inhibition by the novel class III antiarrhythmic azimilide (NE-10064)
3. The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit I(sκ) channels expressed in Xenopus oocytes and I(κS) in guinea pig cardiac myocytes
4. Antiarrythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model
5. Class III effect of azimilide (NE-10064): Prevention of reverse use-dependence in open-chest dogs
6. NE-10064 exhibits class III antiarrhythmic effects after intravenous or oral administration in conscious dogs
7. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug
8. Comparison of hemodynamic effects of 2 type III antiarrhythmic agents in dogs with chronic ischemic left ventricular dysfunction
9. Comparison of azimilide dihydrochloride (NE-10064) and selected class III antiarrhythmic agents in a rabbit model of proarrhythmia
10. Effects of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride
11. PCNONLIN and NONLIN84: Software for the statistical analysis of nonlinear models
12. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocuarine
13. Statistical estimations in pharmacokinetics
14. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party
15. Contrasts for identifying the minimum effective dose
16. Testing the statistical certainty of a response to increasing doses of a drug
17. Circadian rhythmicity of heart rate and QT(c) interval in diabetic autonomic neuropathy: Implications for the mechanism of sudden death
18. Circadian and power spectral changes of RR and QT intervals during treatment of patients with angina pectoris with nadolol providing evidence for differential autonomic modulation of heart rate and ventricular repolarization
19. Diurnal pattern of QT(c) interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events